Kymera Therapeutics Q2 revenue misses expectations, net loss widens

Kymera Therapeutics

11/08/2025 12:07

Overview

Kymera Q2 revenue misses analyst expectations, net income also missed, per LSEG data

Co remains well-capitalized with $1 bln cash, strategic partnership with Gilead

Outlook

Company has cash runway into second half of 2028

Kymera's Gilead partnership could yield up to $750 mln

Result Drivers

GILEAD PARTNERSHIP - Strategic partnership to develop CDK2 degraders, with potential payments up to $750 mln

CASH POSITION - Well-capitalized with $1 bln cash, providing runway into the second half of 2028

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$11.48 mln
$23.40 mln (19 Analysts)
Q2 EPS
-$0.95
Q2 Net Income
Miss
-$76.61 mln
-$66.80 mln (18 Analysts)
Q2 Operating Expenses
$96.03 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 20 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Kymera Therapeutics Inc is $60.00, about 32.3% above its August 8 closing price of $40.62

Press Release: ID:nGNX8Xp8j3

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)